BioCentury
ARTICLE | Clinical News

Anascorp: Phase II/III data

May 25, 2009 7:00 AM UTC

Data from a double-blind, U.S. Phase II/III trial (AL-02/03) in 15 children ages 6 months to 18 years admitted to a pediatric ICU showed that IV Anascorp met the primary endpoint of resolution of the ...